Background: CHOP is considered to be the gold standard for patients with histologically aggressive non-Hodgkin's lymphoma both in limited and advanced stages. In order to determine the maximum tolerable dose of an intensified CHOP regimen, a dose-escalation study of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with non-Hodgkin's lymphoma (NHL) was started.
Introduction
Large-cell non-Hodgkin's lymphoma is a curable disease. However, a large proportion of patients with advanced stage still die of their disease [1] .
On the basis of the Goldie-Coldman hypothesis [2] , all efforts to improve the outcome of patients by circumventing drug-resistance has pointed to increase the number of drugs and the dose-intensity of their administration over a specific time interval versus the standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen.
These points represented the rationale for developing second and third-generation chemotherapy regimens such as ProMACE-CytaBOM (cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate, and procarbazine), MACOP-B (weekly alternation of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), mor M-BACOD, (methotrexate at standard or high dose, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) [3] .
The initial encouraging results from single institution pilot studies with second-and third-generation regimens [4] were not subsequently confirmed by larger randomized trials comparing them with CHOP [3, 5, 6] . Thus, first-generation CHOP regimen still represents the standard choice both for limited and advanced stages.
These negative results can in part be explained by a reduction of dose intensity of the two most active drugs, doxorubicin and cyclophosphamide, in second-and thirdgeneration regimens in order to avoid unacceptable toxicity related to the use of a larger number of drugs [7] [8] [9] [10] [11] [12] .
To assess the role of dose-intensity, CHOP presents the advantage of doxorubicin and cyclophosphamide as the only myelotoxic drugs, thus easily allowing doseescalation of these two drugs [13] .
The aim of this study was to identify the maximum tolerable dose of CHOP (I-CHOP) in an outpatient setting. 
Patients and methods
Patients were enrolled at their first presentation of disease with intermediate-high grade non-Hodgkin's lymphoma in any stage. Furthermore, some cases of low-grade lymphoma with high risk characteristics (e.g., bulky disease, high serum LDH level or disseminated extranodal disease) were also accrued. All T-cell lymphomas were considered as high-grade malignancies. All pathology slides were reviewed by our pathologist, and classified according to Working Formulation for clinical usage [14] and to the Updated Kiel Classification [15] . Eligibility criteria included age from 16 to 70 years, cardiac, hepatic, and renal function within normal value and a normal complete blood count (leukocytes >3,500/cmm and platelets > 100,000/cmm). Patients with CNS involvement or human immunodeficiency virus (HlV)-related lymphoma were excluded.
Pretreatment evaluation included complete physical examination, complete blood count with differential and biochemistry profile, standard chest X-ray, gastrointestinal contrast study, chest and abdomino-pelvic CT scan, bipedal lymphangiography, and bilateral bone marrow biopsy . Informed consent was required. Disease stage was evaluated according to the Ann Arbor staging system [16] and to the International Prognostic Index [17] . istered as intravenous bolus injection; starting from the dose of 2000 mg/m 2 cyclophosphamide was administered as a two-hour infusion. The use of granulocyte-colony-stimulating factor (G-CSF) was planned starting from the dose-level inducing grade 4 neutropenia lasting more than five days or a grade 3 infection, according to NCI common toxicity criteria. Dose-limiting toxicity was defined as either grade 4 neutropenia (absolute neutrophil count <500/cmm) lasting more than seven days despite the use of G-CSF, or grade 3 thrombocytopenia (platelet count below 50,000/cmm) lasting at least seven days or any grade 4 thrombocytopenia, or any grade 4 non-hematological toxicity other than alopecia. If one patient experienced doselimiting toxicity, the previous dose-level of cyclophosphamide was considered as the maximum tolerable dose. The intensification schema is shown in Table 1 .
Treatment plan
Unless otherwise indicated on the basis of clinical presentation of disease, chemotherapy was delivered on an outpatient basis every 21 days. Treatment was delayed by one week if absolute neutrophil count was < 1500/cmm or platelet count was < 100,0000/cmm on the day of the planned course. If adequate recovery did not occur by day 28, a dose-reduction of 25% or more of doxorubicin and cyclophosphamide was given at all subsequent cycles. All patients underwent at least four complete blood count (CBC) on day 8, 10, 12 and 14 of each cycle for monitoring hematological toxicity. Starting from cyclophosphamide 2000 mg/m 2 dose-level, G-CSF at the dose of 5 ug/kg/day was administered subcutaneously to all patients from day seven to day 15 of each cycle.
Patients with limited disease, e.g., stage I-II non bulky disease, were given four cycles of I-CHOP followed by radiotherapy on initially involved sites. Patients with advanced stage (Ann Arbor II bulky, III-IV) were given six cycles of chemotherapy followed by radiotherapy on bulky sites of disease at diagnosis. Radiotherapy was started approximately four weeks after the end of chemotherapy. Total doses ranged from 30.6 to 40 Gy to the prophylactically irradiated regions and from 40 to 50.4 Gy to the involved areas, respectively, with daily fractions of 1.5 to 2 Gy for five days per week, over a four to eight-week period. The majority of patients (89%) were treated by a 6-18 MV linear accelerator, five by a 60 Co teletherapy unit, and one by orthovoltage therapy.
Histological diagnosis
In all cases histologic classification was carried out in buffered formalinfixed, paraffin embedded tissue sections stained with hematoxylin and eosin, Giemsa, PAS-hematoxylin and Gomori's silver impregnation. Immunophenotype on conventional paraffin sections was performed using a modified avidin-biotin peroxidase complex (ABC) method (Vectastain ABC kit, Vector, Burlingame, USA) with an antigen unmasking technique [18] . A panel of monoclonal antibodies was used to detect the lineage of the neoplastic cells (anti T: CD3, Dako, Glostrup, Denmark; CD45RO, UCHL1, Dako; anti-B: CD20, L26, Dako; CD45Ra, F8.ll.13, Serotec, Oxford, UK). Proliferation index was assessed as nuclear immunoreactivity to monoclonal antibody MIB1 (Immunotech, Delta Biologicals, Pomezia, Italy).
Dose-intensity evaluation
Dose intensity was calculated according to the method described by Hryniuk [7] , as milligrams of drugs delivered per square meter per week during the whole treatment program (e.g., from day one of the first cycle to day 22 of the last cycle). At each dose-level, actual (received) dose intensity (ADI) of single-agent doxorubicin and cyclophosphamide was compared to projected dose intensity (PDI). The average relative received dose-intensity was calculated at each doselevel by averaging the ADI to the PDI for each drug in the standard CHOP regimen. PDI and ADI for single-agent doxorubicin and cyclophosphamide at each cyclophosphamide dose-level as well as average PDI and average ADI for the whole regimen, standardized to conventional-dose CHOP were calculated.
Dose-escalation schema
Because of the risk of cumulative cardiotoxicity, the dose of doxorubicin was fixed at 75 mg/m 2 instead of 50 mg/m 2 as in standard CHOP, while vincristine (1.4 mg/m 2 on day 1) and prednisone (100 mg on day 1 through 5) were given at conventional doses. Starting from 1000 mg/m 2 , cyclophosphamide dose was increased by 250 mg/m 2 , in cohorts of at least three consecutive patients per dose-level, provided that no doselimiting toxicity had occurred during the first four treatment courses. Mesna uroprotection, at a dose of forty percent of the cyclophosphamide dose, was given starting from cyclophosphamide dose of 1500 mg/m 2 . Cyclophosphamide up to the dose of 1750 mg/m 2 was adminEvaluation of response and follow-up
In the absence of tumor progression, a complete restaging of disease was performed after the fourth and sixth cycles of chemotherapy. Although this is a dose-finding study an evaluation of treatment outcome was performed. Complete remission was defined as the disappearance of all physical and radiological signs of disease for at least four weeks. Partial remission was defined as a reduction by at least 50% of the sum of the products of the largest tumor diameters recorded before treatment. An increase of 25% or more in the sum of the product of the pre-treatment tumor diameters, as well as the development of new abnormalities were considered as induction failure. After completion of the treatment program, patients in complete remission were monitored every three to four months for the first two years, and every 6 to 12 months thereafter, unless symptoms or signs of disease progression appeared.
Results

Main clinical characteristics
From October 1992 to May 1996, 88 patients were enrolled in the study, one of whom was excluded because of HIV positivity. Thus, the present analysis concerns 87 patients. Main patient characteristics are shown in Table 2 . Most patients (65, or 74.7%) had histologically aggressive B-cell lymphoma (58 centroblastic, six immunoblastic, and one Burkitt's type), five patients had indolent poor prognosis B-cell NHL (one so-called centrocytic, four follicular centroblastic-centrocytic with large cells > 15 per HPF) and 17 T-cell NHL (two T-zone, two large-cell pleomorphous, and 13 large-cell anaplastic). According to Ann Arbor staging system 46 patients were stage I-II and 41 stage III and IV disease. According to the International Prognostic Index, 57 patients had score 1,19 score 2, nine score 3 and two score 4. Thus 76 patients were classified as low to low-intermediate risk and 11 as high-intermediate to high risk. At higher doselevels, more patients were enrolled than at lower ones, due to the fact that toxicity was generally more severe 
Abbreviation: CTX -cyclophosphamide. after the third cycle, and thus, we decided to wait for at least three patients to complete the whole treatment program before proceeding to the next dose-level.
Radiation treatment was given to 57 of 87 patients. In 30 patients the treatment consisted in local regional, in 22 involved fields, and in five previous bulky sites irradiation.
Toxicity Hematological
Hematological toxicities are shown in Tables 3 and 4 . Up to 1500 mg/m 2 of cyclophosphamide, hematological toxicity had a negligible clinical impact and did not differ from standard CHOP-induced toxicity. Most patients experienced grade 4 neutropenia, occurring during the second week of each treatment course. At 2000 mg/m 2 dose-level, both grade 4 neutropenia lasting more than five days and grade 3 infection occurred in two patients (Table 5) , and G-CSF was added to the regimen. Starting from a cyclophosphamide dose of 2000 mg/m 2 , 15 patients required a median of two red blood cell transfusion units (range 1-9) because of anemia with hemoglobin below 8 g/dl. At 3000 mg/m 2 dose-level, dose-limitingtoxicity occurred, with two patients experiencing grade 4 neutropenia lasting more than seven days. Both patients were hospitalized, one because of concomitant grade 4 thrombocytopenia requiring platelet transfusions, and the other one because of grade 3 infection. Thus, ICHOP with cyclophosphamide at 2750 mg/m 2 was defined as maximum tolerable dose (Table 1) .
Non-hematological
Non-hematological effects of the ICHOP regimen are listed in Table 5 . As already mentioned, the use of G-CSF reduced the incidence of infection with no severe episode and no hospitalization at 2000 mg/m 2 as well as at 2250 mg/m 2 dose-level. Mucositis was acceptable and short-lasting, and cystitis was negligible. In one patient, congestive heart failure probably related to cumulative dose of anthracycline developed two years after ICHOP. This was the case of an elderly patient (over 60 years old) who received at diagnosis four cycles of ICHOP followed by four cycles of MINE (Mesna, ifosfamide, mitoxantrone, etoposide) because of partial response. The heart failure resolved after adequate therapy and the patient could then receive further salvage chemotherapy. Overall, nine patients were hospitalized because of toxicity, two of whom at 3000 mg/m 2 dose-level (e.g., over maximum tolerable dose). There was no treatmentrelated death.
Dose-intensity
Timing of cycle administration was globally maintained, with no more than 10% of delays and a few dosereductions (Table 6 ). Treatment discontinuation was necessary in six patients starting from 2250 mg/m 2 dose-level, and were due in one case to disease progression, and in five to toxicity, two of whom at dose-limiting level. The incidence of delays was higher after the third cycle. As reported in Table 7 , ADI standardized to conventional CHOP of both single drug doxorubicin and cyclophosphamide as well as of the whole regimen were maintained, usually approaching PDI. Thus, at the maximum tolerable dose (cyclophosphamide at 2750 mg/m 2 ), a dose intensity of 1.76 compared to standard CHOP was effectively delivered.
Treatment outcome
As previously reported this was a dose-finding study. Nonetheless the treatment outcome was analyzed. In three patients with limited stage disease, response to treatment was not evaluable due to complete removal of all measurable disease before starting chemotherapy (excisional lymphnode biopsy in two cases and gastrectomy in one). Out of 84 patients evaluable for response, the majority (90.5%) achieved complete remission, two partial remission, and six showed disease progression while on treatment and were thus classified as induction failure. Complete response was observed in 40 out of 42 (95%) evaluable patients with limited stage disease, and in 36 out of 42 patients (86%) with advanced disease.
The five patients with low-grade lymphoma were excluded from survival analysis which concerns the 82 patients with histologically aggressive NHL, including all peripheral T-cell cases. At a median follow-up of 33 months, 15 patients relapsed and 13 have died of lymphoma, whereas one patient is still receiving salvage chemotherapy and another patient has died of another cause (suicide) while free of disease. On the overall survival analysis, this patient was considered as dead. Recurrence occurred at a median time of 6.2 months since completion of the treatment program (range 2-30 months). Salvage treatment consisted in non crossresistant chemotherapy in 11 patients, in high-dose chemotherapy followed by autologous bone-marrow or peripheral blood stem-cell rescue in two, while the two remaining patients had very rapid evolution of their disease at relapse with poor performance status thus excluding any kind of treatment. 
Abbreviations: DOX -doxorubicin; PDI -projected dose-intensity; ADI -actual (received) dose-intensity.
Freedom from progression, calculated from the day of the first treatment administration was 84% for an overall survival rate at three years of 87%. As expected, there was a significant difference in both freedom from progression and overall survival between early (95% and 98%, respectively) and advanced (98% and 60%, respectively) stage cases. An analysis among each dose-level, as well as by separating patients receiving a dose of cyclophosphamide up to or higher than 2000 mg/m 2 failed to demonstrate any significant difference in response-rate or in survival.
Discussion
Some retrospective studies focusing on prognostic factors in large-cell lymphomas have suggested that dose intensity of single agent doxorubicin and cyclophosphamide is fundamental in determining outcome of patients with NHL [9] . The inclusion of a larger number of drugs than CHOP in second and third generation regimens implies a sort of 'sacrifice' of dose intensity of cyclophosphamide and doxorubicin, in order to avoid unacceptable toxicities. As doxorubicin and cyclophosphamide are the only myelosuppressive drugs in the CHOP regimen, intensification of CHOP allows doseescalation of the two most important agents available in lymphoma therapy. In the present study, we fixed the dose of doxorubicin at 75 mg/m 2 (e.g., dose intensity at 1.5 x as compared to CHOP) in order not to exceed the maximum tolerable cumulative dose in patients receiving six cycles and escalated the dose of cyclophosphamide in consecutive cohorts of patients as in classical phase I dose-finding studies. Up to 1500 mg/m 2 of cyclophosphamide, hematological toxicities did not differ from what was expected with standard CHOP, with most patients experiencing severe neutropenia, although shortlasting and with a negligible incidence of infectious episodes. At 2000 mg/m 2 , grade 4 neutropenia lasting more than five days occurred in two patients, and G-CSF was added to the regimen at the same dose-level, before proceeding to further escalation of the cyclophosphamide dose. ICHOP with cyclophosphamide at 1750 mg/m 2 was thus defined as maximum tolerable dose without growth factor support. At 3000 mg/m 2 of cyclophosphamide, hematological dose-limiting toxicities occurred in two cases, both requiring platelet transfusion and hospitalization because of severe infection. As regards non hematological toxicity, the incidence of severe mucositis was high, although it did not compromise the timing of cycles. Maximum tolerable dose of ICHOP was thus identified at the lower dose-level e.g., with cyclophosphamide given at 2750 mg/m 2 . Other studies on dose-intensification of CHOP have recently been published. Starting from high doses of cyclophosphamide with doxorubicin given at standard dose, Shipp and coworkers escalated the dose of both drugs identifying maximum tolerable dose at 4000 mg/m 2 of cyclophosphamide and 70 mg/m 2 of doxorubicin, respectively [13] . Otherwise, all patients were admitted to hospital for treatment courses, in order to administer both cyclophosphamide and doxorubicin in two days, with doxorubicin given as a 48 hours continuous infusion. Another trial by Gordon et al. [20] was aimed at intensifying ProMACE-CytaBOM. Whereas the regimen was never given at maximum tolerable dose, the authors were able to administer ProMACE-Cyta-BOM at double doses the standard. In our study, the increase of received dose intensity at maximum tolerable dose of cyclophosphamide and doxorubicin in comparison to standard CHOP were 3.59 and 1.49 respectively, and 1.76 when the whole regimen was considered. Moreover, all patients were treated on an outpatient basis with short-infusion administration. Overall, these trials as well as two other trials focusing on dose-intensification of CHOP [21, 22] demonstrated that with a correct use of growth factor, dose intensity of widely used chemotherapeutic regimens can be safely increased. Nevertheless, whether or not dose-intensification can contribute to improve outcome of patients with aggressive histology non-Hodgkin's lymphoma needs to be proven by randomized trials, which should consider the role of dose-intensity as a prospective end-point. Up to now, the only study [23] prospectively focusing on the prognostic significance of dose-intensity has not demonstrated any role of received dose-intensity on outcome of patients with non-Hodgkin's lymphoma. However, some criticism can arise from this study: first of all, patients of both arms received one course of standard BACOP before randomization, thus sacrificing a crucial moment in the induction of objective response, as it is known that rapidity of response is related to outcome. Secondly, the increase of dose-intensity (1.34 x for escalated-BACOP) can be considered too small to be really defined a 'dose-intensification' of the regimen. Finally, the trial did not plan any dose-escalation for cyclophosphamide [23] .
Our trial, as well as others focusing on dose intensification of CHOP [13, [20] [21] [22] [23] , represents a feasibility study demonstrating the safety of intensified regimen by a proper use of myelopoietic growth factors. Although we achieved a complete remission rate of 90% with a freedom from progression and an overall survival of 84% and 87% at three years, this does not mean that the way to improve outcome of patients with large-cell lymphomas simply consists of intensifying the standard CHOP [24] . The wide use of stem cell reinfusion after high dose chemotherapy, which has become easier in recent years, represents a new strategy to increase doseintensity, mainly focusing on dose-size instead of doseintensity itself. After the PARMA study [25] , high dose chemotherapy has become the standard approach in eligible patients with relapsed large-cell lymphoma. Otherwise, two recent studies have suggested a survival advantage for upfront stem cell transplantation in patients with high-risk aggressive lymphoma [26, 27] with high-risk score according to IPI, although retrospectively evaluated. Otherwise, other randomized trials prospectively comparing standard intensified chemotherapy versus high-dose therapy with stem-cell rescue in patients stratified according to IPI could not demonstrate any advantage even in terms of disease-free survival [28, 29] . Whether or not high-dose strategy will be demonstrated as really effective, is the basis for future trials. Since CHOP has to be considered the control arm of any new treatment regimen for large-cell lymphoma, a comparison of intensified CHOP versus either standard CHOP or high-dose chemotherapy is warranted.
